SLC5A2 and Hypoglycemia: In an indirect meta-analysis, SGLT2-Is achieved better glycemic control and greater weight reduction than DPP4 inhibitors, without increasing the risk of hypoglycemia in patients with T2DM inadequately controlled with insulin [36].